Pathway Markers for Pro-resolving Lipid Mediators in Maternal and Umbilical Cord Blood: A Secondary Analysis of the Mothers, Omega-3, and Mental Health Study by Ellen L. Mozurkewich et al.
fphar-07-00274 September 3, 2016 Time: 12:49 # 1
ORIGINAL RESEARCH
published: 07 September 2016
doi: 10.3389/fphar.2016.00274
Edited by:
Irina Burd,
Johns Hopkins School of Medicine,
USA
Reviewed by:
Karin A. Fox,
Baylor College of Medicine, USA
Azadeh Farzin,
Johns Hopkins University, USA
*Correspondence:
Ellen L. Mozurkewich
emozurkewich@salud.unm.edu
Specialty section:
This article was submitted to
Obstetric and Pediatric
Pharmacology,
a section of the journal
Frontiers in Pharmacology
Received: 14 March 2016
Accepted: 11 August 2016
Published: 07 September 2016
Citation:
Mozurkewich EL, Greenwood M,
Clinton C, Berman D, Romero V,
Djuric Z, Qualls C and Gronert K
(2016) Pathway Markers
for Pro-resolving Lipid Mediators
in Maternal and Umbilical Cord Blood:
A Secondary Analysis of the Mothers,
Omega-3, and Mental Health Study.
Front. Pharmacol. 7:274.
doi: 10.3389/fphar.2016.00274
Pathway Markers for Pro-resolving
Lipid Mediators in Maternal and
Umbilical Cord Blood: A Secondary
Analysis of the Mothers, Omega-3,
and Mental Health Study
Ellen L. Mozurkewich1,2*, Matthew Greenwood3, Chelsea Clinton4, Deborah Berman2,
Vivian Romero5, Zora Djuric6, Clifford Qualls7 and Karsten Gronert3
1 Obstetrics and Gynecology, University of New Mexico, Albuquerque, NM, USA, 2 Obstetrics and Gynecology, University of
Michigan, Ann Arbor, MI, USA, 3 Vision Science Program, Infectious Diseases and Immunity Program, School of Optometry,
University of California at Berkeley, Berkeley, CA, USA, 4 Obstetrics of Gynecology, Duke University, Durham, NC, USA,
5 Obstetrics and Gynecology, Michigan State University, Grand Rapids, MI, USA, 6 Family Medicine, University of Michigan,
Ann Arbor, MI, USA, 7 Clinical and Translational Sciences Center, University of New Mexico, Albuquerque, NM, USA
The omega-3 fatty acids docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA)
are precursors to immune regulatory and specialized pro-resolving mediators (SPM) of
inflammation termed resolvins, maresins, and protectins. Evidence for lipid mediator
formation in vivo can be gained through evaluation of their 5-lipoxygenase (LOX) and
15-LOX metabolic pathway precursors and downstream metabolites. We performed a
secondary blood sample analysis from 60 participants in the Mothers, Omega-3, and
Mental Health study to determine whether SPM and SPM precursors are augmented by
dietary EPA- and DHA-rich fish oil supplementation compared to soy oil placebo. We
also aimed to study whether SPM and their precursors differ in early and late pregnancy
or between maternal and umbilical cord blood. We found that compared to placebo
supplementation, EPA- and DHA-rich fish oil supplementation increased SPM precursor
17-hydroxy docosahexaenoic acid (17-HDHA) concentrations in maternal and umbilical
cord blood (P = 0.02). We found that the D-series resolvin pathway marker 17-HDHA
increased significantly between enrollment and late pregnancy (P = 0.049). Levels of
both 14-HDHA, a maresin pathway marker, and 17-HDHA were significantly greater in
umbilical cord blood than in maternal blood (P < 0.001, both).
Keywords: resolvins, EPA, DHA
INTRODUCTION
A variety of putative health benefits have been attributed to omega-3 fatty acids, including
prevention of cardiovascular disease, reduction of chronic inflammation, reduction in depressive
symptoms, and prevention of insulin resistance (Delarue et al., 2006; Gonzalez-Periz et al., 2006;
Hassan and Gronert, 2009). In pregnancy, omega-3 fatty acid supplementation has been shown
to reduce early preterm births (<32–24 weeks; Makrides et al., 2006, 2010; Szajewska et al., 2006;
Horvath et al., 2007) as well as to decrease risk for infant admission to a neonatal intensive care
unit (Makrides et al., 2010).
Frontiers in Pharmacology | www.frontiersin.org 1 September 2016 | Volume 7 | Article 274
fphar-07-00274 September 3, 2016 Time: 12:49 # 2
Mozurkewich et al. Resolvin Secondary Analysis
Omega-3 fatty acids were originally thought to exert these
beneficial effects by competitively inhibiting formation of pro-
inflammatory arachidonic acid-derived eicosanoids (Gonzalez-
Periz et al., 2006). However, more recently, omega-3 fatty acids
have been shown to be the precursors to novel classes of
specialized pro-resolving mediators (SPM) that are formed by
lipoxygenase (LOX) or cyclooxygenase enzymes analogous to
the formation of the arachidonic acid-derived SPM class of
lipoxins. These ω-3 polyunsaturated fatty acid (PUFA)-derived
mediators are classified as E-series resolvins [eicosapentaenoic
acid (EPA) metabolites], D-series resolvins [docosahexaenoic
acid (DHA) metabolites], maresins (DHA metabolites), and
protectins (DHA metabolites) (Fredman and Serhan, 2011;
Serhan, 2014). In vitro and in vivo experimental evidence
strongly suggests that increased resolvin, maresin, and protectin
formation after dietary supplementation may explain many of the
observed health benefits of dietary ω-3 PUFA supplementation
(Gronert, 2008; Grenon et al., 2015; Murphy, 2015; Serhan et al.,
2015).
In humans, many of the prominent DHA-derived resolvins
are primarily synthesized through the interaction of 15-LOX
with 5-LOX. A key intermediate is the 15-LOX product 17-
hydroperoxy-DHA; its metabolite 17-hydroxy docosahexaenoic
acid (17-HDHA) is pathway marker for the D-series resolvins.
17-Hydroperoxy-DHA is also the rate-limiting intermediate for
the formation of protectin D1, which is 15-LOX product and that
does not require 5-LOX (Serhan and Petasis, 2011). The primary
hematologic cell types that generate 17S-HDHA are eosinophils
(high expression) (Miyata et al., 2013) monocytes (low expression
and high expression in macrophages) and polymorphonuclear
leukocytes (low expression but inducible during resolution)
(Serhan, 2014). By contrast, DHA-derived maresins are formed
via the 12-LOX intermediate 14-hydroperoxy-DHA and further
conversion by 5-LOX. 14-HDHA is the pathway marker for
maresin formation and 12-LOX activity, an enzyme that is
highly expressed in platelets and at lower levels in macrophages
(Barden et al., 2014). 4-HDHA is another 5-LOX metabolite,
that in animal models has been shown to mediate the
antiangiogenic effect of omega-3 fatty acids (Sapieha et al.,
2011) (Figure 1). By contrast, the EPA-derived resolvins are
primarily synthesized through the cytochrome P450 intermediate
18S-hydroxyeicosapentaenoic acid (18S-HEPE), that is further
converted by 5-LOX (Barden et al., 2014).
In healthy, non-pregnant volunteers, endogenous formation
of maresins, resolvins, and protectins may be amplified by dietary
omega-3 fatty acid supplementation (Fredman and Serhan, 2011;
Gomolka et al., 2011). Due to the short half-life and rapid
elimination of the potent resolvins, protectins, and maresins,
direct quantification and detection of SPM in archived tissue
samples may be challenging (Psychogios et al., 2011; Skarke
et al., 2015). However, their specific metabolic intermediates and
pathway markers have established activation of SPM pathways
and their formation in vivo both in humans and animal models
of inflammatory diseases. In particular 18-HEPE, 17-HDHA
and 14-HDHA are established markers for the activation of
the E-series resolvin, D-series resolvin and maresin biosynthetic
pathways, respectively (Weylandt et al., 2012; Barden et al., 2014).
Endogenous synthesis of specialized pro-resolving lipid
mediators and their pathway markers in maternal and fetal
serum has not been previously studied. The proposed study
represents a secondary analysis of stored maternal and fetal
(cord blood) serum samples from subjects who participated in
a double blind randomized controlled trial comparing EPA-rich
fish oil (1060 mg EPA plus 274 mg DHA) and DHA-rich fish
oil (900 mg DHA plus 180 mg EPA) supplementation with
soy oil placebo for prevention of perinatal depression among
women at risk (Mozurkewich et al., 2013). We performed this
ancillary study in order to compare maternal and neonatal
activity of resolvin, protectin, and maresin pathway markers
(RPM). We also aimed to study whether RPM differed in
maternal and umbilical cord blood from subjects who were
supplemented with EPA-rich fish oil, DHA-rich fish oil, versus
placebo. We hypothesized that pathway markers of DHA-derived
resolvins and protectins would be enhanced in umbilical cord
blood compared to maternal blood, due to the preferential
transplacental transport of DHA in late pregnancy. We further
hypothesized that dietary supplementation with EPA- and DHA-
rich fish oils would amplify resolvin, protectin, and/or maresin
pathway activity compared with placebo supplementation.
Ethics
The parent trial was registered at Clinicaltrials.gov at
NCT00711971. This parent study and this secondary analysis
were approved by the University of Michigan Institutional
Review Board at HUM00004684. This secondary analysis was
deemed exempt by the University of New Mexico Health Sciences
Center Human Research Protection Organization where the data
analyses were carried out.
MATERIALS AND METHODS
This study was a secondary analysis using LC/MS/MS (liquid
chromatography/mass spectroscopy/mass spectroscopy) of stored
plasma samples that were collected as part of a prospective,
blinded randomized controlled trial of fish oil supplementation
for prevention of depressive symptoms among women at risk
(Mozurkewich et al., 2013). The parent trial was carried out at
two medical centers in southeastern Michigan, the University of
Michigan Health System and St. Joseph Mercy Health System.
One hundred twenty-six subjects, of whom 118 completed the
trial, enrolled in the study between October 2008 and May
2011. Potential subjects were excluded if they were eating more
than two fish meals weekly, or if they were taking omega-3
fatty acid supplements, including prenatal vitamins with DHA
(Mozurkewich et al., 2013). They were randomly assigned to
receive EPA rich fish oil (1060 mg EPA plus 274 mg DHA),
DHA rich fish oil (900 mg DHA plus 180 mg EPA), or soy oil
placebo, and were followed longitudinally through pregnancy
from their enrollment at 12–20 weeks’ gestation, through 6 weeks
postpartum. Maternal blood was drawn at enrollment (visit 1)
and again at 34–36 weeks gestation (visit 3). Umbilical cord blood
was obtained after the delivery of the infants born to mothers
enrolled in the study (visit 4). Serum aliquots prepared from
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FIGURE 1 | DHA metabolome.
each blood collection and were stored at −70◦C (Mozurkewich
et al., 2013). All samples were processed and stored within 12 h.
Results of the blood sample analyses for fatty acids have been
previously described (Mozurkewich et al., 2013).
This exploratory study involved a subgroup analysis of
serum samples collected from 60 mother–infant pairs of study
participants. Due to cost considerations, it was not possible to
perform analyses for the whole study cohort. Samples for analysis
were selected based on availability of complete sample sets and
adherence to the protocol as ascertained by capsule counts.
Stored samples were analyzed by LC/MS/MS based lipidomic
analysis to quantify levels of ω-3 PUFA-derived SPM. In
brief, 400 pg of class specific deuterated internal standards
prostaglandin E2 (PGE2-d4), lipoxin A4 (LXA4-d5), leukotriene
B4 (LTB4-d4), 15(S)-hydroxyeicosatetraenoic acid [15(S)-
HETE-d8], eicosatetraenoic acid (arachidonic acid-d8) and
docosahexaenoic acid (DHA-d5) were added to each sample
prior to processing and extraction to calculate the recovery of
specific classes of oxygenated fatty acids. Lipid antacids were
extracted by solid phase with SampliQ ODS-C18 cartridges
(Agilent Technologies). Eicosanoids and docosanoids were
identified and quantified by LC/MS/MS-based lipidomics based
on our published methods (Hassan and Gronert, 2009). Extracted
samples were analyzed by a triple-quadrupole linear ion trap
LC/MS/MS system (MDS SCIEX 3200 QTRAP) equipped with a
Kinetex C18 mini-bore column. The mobile phase was a gradient
of A [water/acetonitrile/acetic acid (72:28:0.01, v:v:v)] and B
[isopropanol/acetonitrile (60:40, v:v)] with a 450 µl/min flow
rate. MS/MS analyses was performed in negative ion mode
and prominent fatty acid metabolites quantified by multiple
reaction monitoring (MRM mode) using established and specific
transitions as previously described (González-Périz et al., 2009;
Hassan and Gronert, 2009; Sapieha et al., 2011; von Moltke
et al., 2012; Kalish et al., 2013; Pruss et al., 2013). Calibration
curves (1–1000 pg) and specific LC retention times for each
compound were established with synthetic standards (Cayman
Chemical, Ann Arbor, MI, USA). Structures were confirmed
for selected autacoids by MS/MS analyses using enhanced
product ion mode with appropriate selection of the parent ion
in quadrupole 1. EPA, DHA, and arachidonic acid metabolomes
were constructed. For inclusion, levels of ω-3 PUFA-derived
SPM needed a signal-to-noise ratio of at least 3:1. When the
signal-to-noise ratio did not meet this inclusion criteria, we used
the lower limits of detection, which were 1 pg/ml for 4-HDHA,
5 pg/ml for 14-HDHA, and 2 pg/ml for 17-HDHA.
Statistics
For comparison of the baseline characteristics between the
three treatment groups, we used analysis of variance (ANOVA).
Comparisons for categorical variables were done using Fisher’s
exact tests. For other outcome measures computed descriptive
statistics reported as mean and standard error of the mean
for continuous data and frequency (%) for binary and
categorical data. For values below the limits of detection,
we imputed the lower limit of detection for the assay
used. Data with right-skewed distributions were logarithmically
transformed. We analyzed log-transformed resolvin pathway
marker concentrations across visits 1, 3, and 4 (with visit 4
representing neonatal cord blood), with repeated measures (RM)
ANOVA with “visit” as the repeated factor and the three “groups”
(EPA, DHA, and placebo) as the grouping factor. Where there
was no difference between individual treatment groups versus
placebo, the treatment groups (EPA and DHA) were combined
for subsequent RM ANOVA exploratory analysis. In instances
in which significance was found by RM ANOVA, further
exploratory analyses were carried out in the following manner.
Post hoc tests of change at visit 3 (post-supplementation) were
done by paired t-test. Post hoc comparisons between groups were
done using unpaired t-tests. Pearson’s correlation coefficient was
computed to describe the relationship between log-transformed
serum DHA levels at each study visit and log-transformed 4-
HDHA, 14-HDHA, and 17-HDHA. For the purposes of the
correlation analyses, the values below the lower limit of detection
were removed. An additional correlation analysis was carried
out to evaluate the relationship between maternal DHA at 34–
36 weeks and cord blood 17-HDHA. A P-value of 0.05 was
considered statistically significant. We conducted an exploratory
analysis of the effect of labor on 17-HDHA formation by
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comparing log transformed 17-HDHA concentrations in cord
blood collected after cesarean section without labor versus cord
blood from birth after labor using unpaired t-tests.
RESULTS
The baseline demographic characteristics of the study subjects
in the subset chosen for this analysis did not differ significantly
between the treatment groups. Capsule compliance was similar
between the three groups with subjects in the EPA group having
an overall compliance of 69%, subjects in the DHA group
with 71% compliance, and subjects in the placebo group with
76% compliance. This difference was not statistically significant
(P = 0.60, generalized linear models). There was no difference
in mean age at screening, gravidity, parity, or history of prior
preterm delivery among the treatment groups (ANOVA, all
P ≥ 0.50) There was no difference in ethnicity or race (Fisher’s
exact test, both P > 0.35; Table 1).
TABLE 1 | Demographic table.
EPA DHA Placebo Significance
N 19 21 20
Age at
screening
29.0 ± 5.5 30.4 ± 4.8 30.9 ± 6.1 NS
Gravidity 2.37 ± 1.38 2.33 ± 1.15 2.20 ± 1.91 NS
Parity, term 0.68 ± 0.95 0.90 ± 1.04 0.60 ± 0.88 NS
Preterm 0.105 ± 0.315 0.095 ± 0.301 0.200 ± 0.523 NS
Av.
compliance
0.69 ± 0.25 0.71 ± 0.20 0.76 ± 0.22 NS
White 16 17 16 NS
Av = average; NS = not significant.
D-series resolvins, E-series resolvin, protectins, and
maresins were not consistently detected; peaks were below
acceptable signal-to-noise ratio for the 3200 QTRAP MRM-
based identification and quantification. The E-series resolvin
pathway marker, 18-HEPE, was below detectable limits in 96%
of the samples. Thus no further analysis of the EPA metabolome
was carried out.
There was no significant difference in 4-HDHA levels between
the groups at study entry or at any subsequent study visit. Log
transformed 4-HDHA levels did not significantly differ across the
study visits and were not significantly different in the maternal
blood versus umbilical cord blood (Figure 2). Log transformed
4-HDHA concentrations were significantly correlated with DHA
levels (Pearson’s correlation coefficient 4 = 0.51, P < 0.001;
Figure 3).
Log transformed 14-HDHA did not differ significantly
between early and late pregnancy. 14-HDHA levels were
significantly increased in umbilical cord blood compared to
maternal blood at both maternal blood draw time points
(P < 0.001). There was no significant treatment effect of EPA-
and DHA-rich fish oil supplementation compared to placebo
on 14-HDHA levels, in either maternal blood or umbilical cord
blood (Figure 4). However, in an analysis of combined blood
samples from all study visits, 14-HDHA levels were significantly
correlated with DHA levels (Pearson’s correlation coefficient 0.47,
P < 0.001; Figure 5).
For the total cohort, 17-HDHA levels significantly increased
in maternal blood between enrollment and 34–36 weeks
(P= 0.049). Concentrations of 17-HDHA in umbilical cord blood
were significantly greater than in maternal blood both at study
entry and at 34–36 weeks gestation (P < 0.001; Figure 6). In the
total sample set, 17-HDHA levels were significantly correlated
with DHA levels (Pearson’s correlation coefficient 0.34, P < 0.02;
Figure 7).
FIGURE 2 | Maternal and cord blood log 4-HDHA concentration.
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FIGURE 3 | Correlation of log DHA fraction with log 4-HDHA
concentration.
When the EPA- and DHA-rich fish oil groups were
individually compared with placebo using repeated measures
modeling, there was a trend toward higher 17-HDHA activity
that did not reach significance (P = 0.07). By contrast, when
the two supplementation groups were combined for the purpose
of analysis, 17-HDHA activity was significantly higher in the
combined EPA- and DHA-rich fish oil group than in the placebo
supplemented group (P = 0.02).
However, when the EPA- and DHA-rich oil groups were
together compared with placebo at the post-supplementation
time points using the t-test, there were no significant differences
between the treatment groups and placebo at either of the post-
supplementation time points. Although there was a trend toward
treatment effect for supplementation at visit 3 (P = 0.11, t-test)
this effect was not statistically significant. Likewise, although
concentrations of 17-HDHA in umbilical cord blood were higher
in the treatment groups as compared to placebo, this trend was
not significant (P = 0.33). Of interest, cord blood levels of 17-
HDHA were 5-fold higher after exposure to labor than in the
instance of elective cesarean section, but this difference did not
reach statistical significance.
DISCUSSION
The main finding of our study is that the maresin pathway
precursor 14-HDHA and the resolvin pathway marker 17-HDHA
were significantly enhanced in cord serum compared to maternal
serum in early and late pregnancy. This finding is consistent with
the observation of augmentation of DHA percentage in umbilical
cord serum compared to maternal serum that we observed in the
parent study and that has also been reported in other studies
(Mozurkewich et al., 2013; Baack et al., 2015). Our study also
suggested a treatment effect for EPA- and DHA-rich fish oil
supplementation for the resolvin pathway precursor 17-HDHA,
but prospective randomized studies are needed to determine
whether resolvins, protectins, and maresins, themselves, are
augmented by supplementation (Colas et al., 2014).
Previous studies examining the presence of SPM in adults
have looked at subsets with specific diseases, including asthma,
Alzheimer’s disease, multiple sclerosis, chronic kidney disease,
peripheral artery disease, and rheumatoid arthritis (Serhan, 2014;
Grenon et al., 2015; Mas et al., 2016) as well as in unselected
adults (Psychogios et al., 2011). In the reproductive sphere,
FIGURE 4 | Maternal and cord blood log 14-HDHA concentrations.
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FIGURE 5 | Correlation of log DHA fraction with log 14-HDHA
concentrations.
maternal omega-3 fatty acid supplementation with 3.7 g DHA
plus EPA was shown to increase resolvin and protectin precursors
in human placental tissues; likewise, a high n-3 PUFA diet has
been shown to increase SPM precursors in rat placentas (Jones
et al., 2013; Keelan et al., 2015). This study differs from these prior
evaluations in that it assessed resolvin, protectin, and maresin
pathway activity in human umbilical cord blood in relation to
maternal dietary supplementation with DHA and EPA.
Our study was limited by the small sample size as well
as cost constraints that precluded analysis of the entire trial
FIGURE 7 | Correlation of log DHA fraction with log 17-HDHA
concentrations.
cohort. Similarly, the sample subset analyzed was not randomly
chosen, but was selected based on maternal compliance with
supplementation and by availability of complete sample sets.
In terms of quantifying ω-3 PUFA-derived SPM our analysis
was limited to quantifying DHA-derived resolvin, maresin, and
protectin pathway markers, which likely was due to using an
LC/MS/MS system with 1–10 pg limits of quantification. The
DHA-derived resolvin pathway precursors we evaluated were
below the limits of detection in some of our samples, and the
precursors of the E-series resolvins were detected in only a few
FIGURE 6 | Maternal and cord blood log 17-HDHA concentrations.
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samples. In addition, although several investigations in animal
models suggest that SPM may act to inhibit preterm delivery and
insulin resistance (González-Périz et al., 2009; Hellmann et al.,
2011; Yamashita et al., 2013), our study was not designed to
determine whether increased SPM levels after supplementation
would confer any clinical benefit.
Another potential weakness of this study is the possibility
that autoxidation may have led to higher levels of some pathway
markers rather than enzymatic conversion of DHA. Our protocol
for the timing of specimen processing and storage was also
chosen to minimize autoxidation artifacts. The patients and
treatment-specific lipidomic profiles and differing levels of the
monohydroxy metabolites 4-HDHA, 14-HDHA, and 17-HDHA
in each sample also suggest that autoxidation did not significantly
contribute to the overall lipidomic profiles.
It is important to note that resolvins, protectins, and
maresins are produced in self-limited inflammatory leukocyte-
rich exudates and are temporally regulated during the resolution
phase of acute inflammation (Serhan, 2014). This may explain
the increase in cord blood levels of 17-HDHA after exposure
to labor, which requires activation of inflammatory pathways,
compared to elective cesarean section (Gonzalez et al., 2011).
Lipid mediators have also been found to be 10–100 times higher
in serum compared to plasma (Colas et al., 2014). Finally, higher
levels of SPMs were recently reported in human milk when
compared to those observed in peripheral blood samples of
healthy individuals (Weiss et al., 2013).
Thus, future research examining SPM pathway activity in
serum during phases of acute inflammation, such as normal
and abnormal labor would be of great interest. We have
previously reported that DHA-rich fish oil supplementation
increased DHA levels in maternal and umbilical cord blood,
compared to placebo (Mozurkewich et al., 2013). While we did
not demonstrate any effect of fish oil dietary supplementation
on SPM themselves, the trend toward treatment effect of
supplementation on resolvin pathway markers in our small
sample should lead to larger studies evaluating the effect of
supplementation on SPM and any associations with clinical
outcomes. Further, given the reported high concentration of
SPMs in human milk, it would be beneficial to collect the serum of
breastfed neonates of mothers supplemented with omega-3 fatty
acids for examination of newborn host defense and development.
Continued research on specialized SPM profiling is also needed
because human resolution phenotypes have only recently been
developed (Morris et al., 2010). Now that studies have proven
the presence of SPMs in adult and fetal tissue, as well as their
potential for modulation, the stage has been set for further
identification of SPM function and relationship to nutrition and
disease. Specifically, further research is needed to elucidate the
potential benefits for prenatal augmentation of RPM in the fetal
compartment.
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